Tharimmune (THAR) Stock Overview
A clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
THAR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Tharimmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.59 |
| 52 Week High | US$9.08 |
| 52 Week Low | US$0.95 |
| Beta | 1.45 |
| 1 Month Change | -0.38% |
| 3 Month Change | -10.69% |
| 1 Year Change | 25.73% |
| 3 Year Change | -98.23% |
| 5 Year Change | n/a |
| Change since IPO | -99.80% |
Recent News & Updates
Shareholder Returns
| THAR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.6% | 1.1% | 1.3% |
| 1Y | 25.7% | 26.4% | 15.8% |
Return vs Industry: THAR matched the US Biotechs industry which returned 26.4% over the past year.
Return vs Market: THAR exceeded the US Market which returned 15.8% over the past year.
Price Volatility
| THAR volatility | |
|---|---|
| THAR Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: THAR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: THAR's weekly volatility has decreased from 35% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 3 | Mark Wendland | www.tharimmune.com |
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States. It is involved in the development of TH104 for the proposed indication of temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with opioids, as well as is in phase 2 study in patients with chronic pruritus in primary biliary cholangitis. The company also engages in the development of TH023 to treat autoimmune indications; and HS1940, a bispecific biologic against PD-1 and vascular endothelial growth receptor antibody that targets both receptors.
Tharimmune, Inc. Fundamentals Summary
| THAR fundamental statistics | |
|---|---|
| Market cap | US$90.77m |
| Earnings (TTM) | -US$10.32m |
| Revenue (TTM) | n/a |
Is THAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THAR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.32m |
| Earnings | -US$10.32m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.2% |
How did THAR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/28 05:51 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tharimmune, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashok Kumar | ThinkEquity LLC |